Health ❯ Healthcare ❯ Biotechnology

Immunotherapy

Cancer Treatment Anktiva CAR T Cell Therapy Antibody Therapies Bladder Cancer T Cell Receptors

Investors Vie to Lead ImmunityBio Securities Suit

An FDA warning about misleading Anktiva promotions has turned investor losses into the central issue in the fight over who will control the case.

ImmunityBio Investors Face May 26 Deadline in Securities Class Action Over FDA Ad Rebuke

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

ImmunityBio Sued in Securities Class Action Over Anktiva Marketing Claims

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion